The Arab Drug Company (EGX:ADCI)
254.67
-1.52 (-0.59%)
At close: Oct 22, 2026
The Arab Drug Company Ratios and Metrics
Market cap in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 3,056 | 2,886 | 1,209 | 482 | 401 | 275 | |
Market Cap Growth | 11.66% | 138.70% | 150.60% | 20.27% | 45.83% | -30.70% |
Enterprise Value | 3,497 | 3,362 | 1,638 | 766 | 505 | 302 |
Last Close Price | 254.67 | 240.47 | 97.36 | 36.05 | 27.93 | 17.42 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PE Ratio | 13.15 | 12.42 | 5.90 | 5.46 | 5.64 | 3.61 |
Forward PE | - | 8.58 | 8.58 | 8.58 | 8.58 | 8.58 |
PS Ratio | 2.23 | 2.11 | 1.08 | 0.61 | 0.63 | 0.55 |
PB Ratio | 4.07 | 3.84 | 1.95 | 1.05 | 1.05 | 0.81 |
P/TBV Ratio | 4.07 | 3.84 | 1.95 | 1.05 | 1.05 | 0.81 |
P/FCF Ratio | 21.44 | 20.25 | - | - | 16.49 | - |
P/OCF Ratio | 11.79 | 11.13 | 7.36 | 3.55 | 4.58 | 8.37 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
EV/Sales Ratio | 2.55 | 2.45 | 1.47 | 0.98 | 0.80 | 0.60 |
EV/EBITDA Ratio | 8.35 | 8.06 | 4.83 | 6.35 | 5.08 | 3.01 |
EV/EBIT Ratio | 9.26 | 8.90 | 5.25 | 6.48 | 5.21 | 3.32 |
EV/FCF Ratio | 24.54 | 23.59 | - | - | 20.77 | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Debt / Equity Ratio | 0.75 | 0.75 | 0.83 | 1.13 | 0.50 | 0.44 |
Debt / EBITDA Ratio | 1.34 | 1.34 | 1.51 | 4.26 | 1.91 | 1.51 |
Debt / FCF Ratio | 3.93 | 3.93 | - | - | 7.90 | - |
Net Debt / Equity Ratio | 0.59 | 0.59 | 0.70 | 0.62 | 0.37 | 0.33 |
Net Debt / EBITDA Ratio | 1.06 | 1.06 | 1.28 | 2.36 | 1.42 | 1.11 |
Net Debt / FCF Ratio | 3.09 | 3.09 | -12.50 | -1.89 | 5.82 | -1.94 |
Asset Turnover | 0.96 | 0.96 | 0.91 | 0.87 | 1.01 | 0.99 |
Inventory Turnover | 2.43 | 2.43 | 2.31 | 2.12 | 1.71 | 1.61 |
Quick Ratio | 0.51 | 0.51 | 0.63 | 1.01 | 0.73 | 0.68 |
Current Ratio | 1.43 | 1.43 | 1.52 | 1.93 | 2.49 | 2.31 |
Return on Equity (ROE) | 38.62% | 38.62% | 42.26% | 24.43% | 22.88% | 23.48% |
Return on Assets (ROA) | 16.55% | 16.55% | 15.87% | 8.13% | 9.66% | 11.12% |
Return on Invested Capital (ROIC) | 24.76% | 26.01% | 26.85% | 14.45% | 15.43% | 19.53% |
Return on Capital Employed (ROCE) | 39.70% | 39.70% | 36.00% | 15.00% | 19.80% | 23.10% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Earnings Yield | 7.60% | 9.17% | 18.85% | 21.32% | 20.64% | 27.74% |
FCF Yield | 4.66% | 4.94% | -2.86% | -31.14% | 6.07% | -20.74% |
Dividend Yield | 1.96% | 2.08% | 4.14% | 10.39% | 6.73% | 10.47% |
Payout Ratio | 45.43% | 45.43% | 27.70% | 35.11% | 45.29% | 57.06% |
Buyback Yield / Dilution | - | - | - | - | 11.45% | 2.11% |
Total Shareholder Return | 1.96% | 2.08% | 4.14% | 10.39% | 18.19% | 12.58% |